Annual report [Section 13 and 15(d), not S-K Item 405]

Summary of Significant Accounting Policies (Tables)

v3.26.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2025
Summary of Significant Accounting Policies  
Schedule of significant expense categories

  ​ ​ ​

Year Ended

December 31, 

December 31, 

  ​ ​ ​

2025

  ​ ​ ​

2024

Operating expenses:

Acquired in-process research and development

$

12,030,389

$

Clinical

7,251,179

1,153,345

Chemical, manufacturing and controls

1,027,799

710,055

Research and preclinical

58,198

505,750

Regulatory

43,477

20,065

Other research and development costs

1,455,029

1,141,698

Total research and development

21,866,071

3,530,913

General and administrative expenses

6,102,374

8,696,335

Total operating expenses

$

27,968,445

$

12,227,248

Loss on debt conversion with related party

6,134,120

Interest (income) expense, net

(96,938)

92,192

Loss on fixed asset disposal

2,731

Exchange loss, net

 

27,916

 

30,787

Net loss before income taxes

$

34,036,274

$

12,350,227